For the quarter ending 2026-03-31, DNA had -$23,702K decrease in cash & cash equivalents over the period. -$48,619K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Goodwill impairment | - | 0 | 0 | 0 |
| Restructuring related impairment charges | - | 0 | - | - |
| Non-cash customer consideration | - | 0 | - | - |
| Loss on equity method investments | - | 0 | - | - |
| Loss on investments | - | -16,411 | - | - |
| Change in fair value of notes receivable | - | 5,685 | - | - |
| Change in fair value of warrant liabilities | - | 0 | 0 | 0 |
| Net loss | - | -80,751 | -80,755 | -151,257 |
| Net loss from continuing operations | -76,059 | - | - | - |
| Depreciation and amortization | 12,799 | 13,663 | 14,168 | 31,159 |
| Impairment of right-of-use asset | - | - | 0 | 0 |
| Stock-based compensation | 15,853 | 21,027 | 17,841 | 42,678 |
| Loss on investments | -939 | - | 3,683 | -3,958 |
| Loss on deconsolidation of subsidiary | - | - | 0 | - |
| Change in fair value of notes receivable | -1,074 | - | -400 | -5,285 |
| Change in fair value of contingent consideration | 0 | 0 | 0 | 4,232 |
| Loss on deconsolidation of subsidiaries | - | 0 | - | - |
| Impairment of long-lived assets | - | 0 | - | - |
| Deferred income tax benefit | - | -1,364 | - | - |
| Loss on disposal of equipment | - | 0 | - | - |
| Non-cash lease expense | 7,114 | 7,633 | 7,583 | 14,866 |
| Non-cash in-process research and development | - | 0 | 0 | 0 |
| Accretion of discount on marketable securities | 120 | 888 | 2,502 | - |
| Other non-cash activity | -185 | -453 | -1,565 | -46 |
| Changes in operating assets and liabilities | 242 | 1,818 | -757 | 412 |
| Prepaid expenses and other current assets | -5,930 | 5,177 | -2,202 | 2,272 |
| Operating lease right-of-use assets | 0 | 0 | 0 | -3,814 |
| Other non-current assets | -94 | -334 | -87 | 125 |
| Accounts payable | - | -2,992 | - | - |
| Accounts payable, accrued expenses and other current liabilities | -11,601 | -6,615 | 22,116 | -5,125 |
| Deferred revenue | -2,606 | -5,184 | -3,533 | -23,676 |
| Operating lease liabilities, current and non-current | -4,995 | -9,139 | -7,155 | -11,638 |
| Other non-current liabilities | -758 | 7,004 | -697 | 5,156 |
| Net cash used in operating activities - continuing operations | -46,433 | - | - | - |
| Deconsolidation of subsidiaries - cash | - | 0 | - | - |
| Net cash used in operating activities - discontinued operations | -253 | - | - | - |
| Business acquisitions, net of cash acquired | - | 0 | 0 | 0 |
| Net cash used in operating activities - continuing operations | -46,686 | -47,678 | -31,606 | -91,775 |
| Purchases of marketable debt securities | 83,161 | 16,792 | 81,706 | 320,132 |
| Maturities of marketable debt securities | 108,178 | 85,884 | 73,599 | - |
| Purchases of notes receivable | - | 0 | - | - |
| Proceeds from sale of marketable debt securities | - | 25,899 | -64,958 | 64,958 |
| Proceeds from sales of marketable equity securities | - | 0 | - | - |
| Proceeds from sale of equipment | - | 574 | 0 | - |
| Purchases of property and equipment | 1,933 | 5 | 0 | 7,660 |
| Other | -48 | 461 | -249 | -262 |
| Net cash provided by (used in) investing activities | 23,132 | 95,099 | -72,816 | -262,572 |
| Proceeds from atm offering | - | 9,152 | 10,317 | - |
| Payment of issuance costs related to atm offering | - | 985 | 355 | - |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Contingent consideration payment | - | 0 | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | - | 0 | - | - |
| Other | - | - | 0 | - |
| Payment of equity issuance costs and other | - | 0 | - | - |
| Principal payments on finance leases | 19 | 25 | 24 | 305 |
| Net cash used in financing activities | -19 | 8,142 | 9,938 | -305 |
| Effect of foreign exchange rates on cash and cash equivalents | -129 | -152 | 93 | 260 |
| Net decrease in cash, cash equivalents and restricted cash | -23,702 | 55,411 | -94,391 | -354,392 |
| Cash and cash equivalents at beginning of period | - | - | 605,743 | - |
| Cash and cash equivalents at end of period | - | - | 156,960 | - |
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)